TF and neoplasm: As the tumor burden can fluctuate over time, with lower levels after treatment response and increasing levels as the tumor develops resistance to therapy, comprehensive genomic profiling tests could be used to complement DELFI-TF to identify appropriate therapies at the time of progression.